

Open Peer Review on Qeios

Omapatrilat

National Cancer Institute

Source

National Cancer Institute. <u>Omapatrilat</u>. NCI Thesaurus. Code C1782.

A vasopeptidase inhibitor with antihypertensive activity. Omapatrilat exerts its effect by inhibiting angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP). ACE inhibition results in inhibition of the renin-angiotensin-aldosterone system thereby leading to the reduction of vasoconstriction. Inhibition of NEP leads to the inhibition of hydrolyzation of a number of endogenous vasoactive peptides, such as bradykinin and substance P and as NEP is the principal enzyme degrading natriuretic peptides, NEP inhibition also results in an increase in natriuretic peptidase circulation. Ultimately both effects result in blood vessel relaxation.

Qeios ID: 316VR5 · https://doi.org/10.32388/316VR5